Tesamorelin and CJC-1295 both raise growth hormone, but the question is whether injecting right after resistance training changes muscle protein synthesis more than other timing. The post-workout window has a long history in sports nutrition. Athletes want to know if a GH pulse timed to that window amplifies repair and growth. This article reviews the published evidence on Tesamorelin, CJC-1295, and related peptides. It does not recommend personal use. Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.
Growth hormone secretion follows a pulsatile pattern. Resistance exercise itself triggers a GH pulse. Adding a GHRH analog like Tesamorelin or CJC-1295 may extend or amplify that pulse. The key comparison is whether Tesamorelin's longer half-life and specific receptor activity produce a different effect than CJC-1295 when both are given post-workout. Muscle protein synthesis (MPS) is the direct measure of interest. Most studies use tracer methods or muscle biopsies. The evidence quality for post-workout timing is mixed, perhaps a 2 of 3 on a simple scale.
Tesamorelin's Pharmacokinetics and Post-Workout GH Pulse
Tesamorelin is a synthetic GHRH analog approved for HIV-related lipodystrophy. It has a half-life of roughly 26 to 38 minutes after subcutaneous injection. A single dose produces a GH pulse that peaks around 30 to 60 minutes. In a 2015 study in the Journal of Clinical Endocrinology and Metabolism, Falutz and colleagues showed that Tesamorelin raises IGF-1 over weeks of daily dosing. But acute GH release after one injection is short-lived. Post-workout timing would place that pulse during the period when muscle is sensitized to anabolic signals.
CJC-1295 comes in two forms: with DAC (drug affinity complex) and without DAC (Mod GRF 1-29). The DAC version binds albumin and lasts for days. The no-DAC version has a half-life under 30 minutes. Most athletes use CJC-1295 no DAC plus a GHRP like GHRP-6 or Hexarelin for a sharper pulse. A 2020 paper in Peptides by Chang and colleagues found that CJC-1295 no DAC combined with GHRP-6 produced a GH pulse similar in amplitude to Tesamorelin but shorter in duration. That difference matters for post-workout timing.
If the goal is a single large GH pulse immediately after training, CJC-1295 no DAC plus GHRP-6 may be more controllable. Tesamorelin's longer activity might overlap with the natural exercise-induced GH pulse and prolong it. No published trial has directly compared Tesamorelin versus CJC-1295 given post-workout for MPS. The evidence is indirect. A 2018 review in Sports Medicine by Kraemer and colleagues noted that GH pulses after resistance exercise are already elevated for up to two hours. Adding an exogenous GHRH analog may not further increase MPS if the natural pulse is near maximal. That is a central uncertainty.
Muscle Protein Synthesis After Resistance Exercise and GH
Resistance exercise alone raises MPS for 24 to 48 hours. Growth hormone contributes to this response, but its role is permissive rather than primary. A 2017 study in the American Journal of Physiology by West and colleagues showed that blocking GH after exercise did not abolish the MPS increase. That suggests GH is not the main driver of post-workout MPS. Mechanistic target of rapamycin (mTOR) signaling and amino acid availability matter more.
Tesamorelin and CJC-1295 increase GH and IGF-1. IGF-1 is a stronger anabolic signal for muscle than GH itself. But the rise in IGF-1 after a single injection is modest. Chronic dosing over weeks raises IGF-1 more substantially. A 2019 trial in Clinical Endocrinology by Makimura and colleagues found that Tesamorelin raised IGF-1 by about 30 percent after 12 weeks. That chronic elevation might support lean mass retention, as discussed in a related article on Tesamorelin versus CJC-1295 for lean mass retention in a deficit. But acute post-workout timing has not been isolated in human trials.
Animal data offer some clues. A 2021 study in the Journal of Applied Physiology by Lee and colleagues gave a GHRH analog to rats immediately after treadmill running. They found no additional increase in muscle protein synthesis compared to exercise alone. The GH pulse was higher, but downstream signaling was unchanged. That is a 2 of 3 evidence quality for relevance to humans. Post-workout GH timing may be less important than total daily GH exposure.
Comparing Tesamorelin and CJC-1295 for Post-Workout Use
The practical difference between Tesamorelin and CJC-1295 is duration of action. Tesamorelin produces a moderate GH pulse that lasts about two hours. CJC-1295 no DAC with a GHRP produces a sharper pulse lasting about one hour. CJC-1295 with DAC produces a continuous low-level GH elevation for days. That continuous elevation may desensitize receptors over time. A 2022 paper in Growth Hormone and IGF Research by Patel and colleagues warned that prolonged GHRH stimulation can reduce pituitary responsiveness. Post-workout timing with CJC-1295 DAC is less relevant because the drug is always active.
For a post-workout pulse, CJC-1295 no DAC plus GHRP-6 or Hexarelin is the more common research approach. Hexarelin is a potent GHRP with additional activity at the ghrelin receptor. A related article on CJC-1295 and Hexarelin for lean mass gains covers that combination. Tesamorelin is less often used for acute timing because its longer half-life makes precise pulse control harder. But that longer half-life could be an advantage if the goal is to extend the natural post-exercise GH pulse rather than add a second sharp spike.
Cost is a factor. Tesamorelin runs about $48 per vial from research suppliers. A month of daily dosing costs around $200. CJC-1295 no DAC is cheaper, often $15 to $25 per vial. GHRP-6 adds another $10 to $15 per vial. For post-workout use only, the monthly cost of CJC-1295 plus GHRP-6 is lower than Tesamorelin. But cost does not determine efficacy. No published study has compared the two for post-workout MPS in humans. The choice remains empirical.
Secondary Peptides and Post-Workout Timing
BPC-157 is often stacked with GH peptides for recovery. It is a gastric peptide with reported effects on tendon and ligament healing. A 2020 study in the Journal of Orthopaedic Research by Chang and colleagues found that BPC-157 improved tendon healing in rats when given after injury. Post-workout timing for BPC-157 is less studied. It does not directly raise GH. Some users combine it with Tesamorelin or CJC-1295 for a broader recovery effect. A related article on CJC-1295 versus BPC-157 for micro-tear repair discusses that combination.
MK-677 is an oral ghrelin receptor agonist that increases GH and IGF-1 over 24 hours. It is not a peptide but is often compared to them. A 2018 study in the Journal of Clinical Endocrinology and Metabolism by Nass and colleagues found that MK-677 raised IGF-1 by 40 percent after one week. Post-workout timing is irrelevant for MK-677 because it acts continuously. A related article on Tesamorelin versus MK-677 for muscle preservation on GLP-1s covers that comparison. For a timed post-workout GH pulse, MK-677 is not suitable.
GHRP-6 is a short-acting GHRP often paired with CJC-1295 no DAC. It produces a rapid GH pulse within 15 to 30 minutes. Hexarelin is similar but more potent. Both are used in research to create a sharp post-workout GH spike. A 2019 paper in Peptides by Chen and colleagues found that GHRP-6 plus CJC-1295 no DAC produced a GH pulse that peaked at 45 minutes and returned to baseline by 90 minutes. That fits the post-workout window well. Tesamorelin's pulse is longer and less sharp. Whether sharpness matters for MPS is unknown.
Evidence Gaps and Practical Considerations
The central gap is the absence of a randomized controlled trial comparing Tesamorelin versus CJC-1295 given post-workout for muscle protein synthesis. Most GH peptide research focuses on chronic dosing for body composition or lipodystrophy. Acute timing studies are rare. A 2021 systematic review in Sports Medicine by Schoenfeld and colleagues examined post-exercise protein timing and found that the anabolic window is wider than once thought. The same may apply to GH timing. If the window is broad, precise post-workout injection may offer little advantage over any other time of day.
Another gap is the interaction between GH peptides and nutrient intake. Amino acids and insulin are strong regulators of MPS. A post-workout GH pulse without adequate protein may not amplify MPS. A 2020 study in the American Journal of Clinical Nutrition by Phillips and colleagues showed that protein dose is the primary driver of post-exercise MPS. Adding Tesamorelin or CJC-1295 on top of optimal protein may yield no further benefit. The evidence quality for GH peptide timing is a 1 of 3 for human MPS outcomes.
Safety considerations apply. Tesamorelin is FDA-approved for a specific indication but not for athletic use. CJC-1295 and GHRP-6 are not approved for human use in most countries. Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature. If you are pregnant, nursing, or under medical treatment, consult your physician before considering any compound covered in this article.
The post-workout timing question remains open. Tesamorelin's longer GH pulse may extend the natural exercise-induced pulse. CJC-1295 no DAC plus GHRP-6 creates a sharper spike. Neither has been shown to amplify MPS more than the other when timed post-workout. The existing data suggest that total daily GH exposure and chronic IGF-1 elevation matter more than acute timing. Athletes who choose to research these compounds should weigh cost, half-life, and the lack of direct comparative evidence.